Smart Symptom Tracking with ALEX for GI Health in Young Adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional pilot study compares the Smart Symptom Tracking ALEX app to standard symptom-tracking methods for monitoring gastrointestinal symptoms in young adults at risk for early-onset colorectal cancer. Participants use a digital AI-powered platform that prompts for symptoms, provides coaching, reminders, and education over a four-week period. The study aims to determine if the app yields more detailed symptom data and improves self-monitoring compared with traditional paper-based logs. Eligibility includes adults 18–44 who are concerned about their GI health, able to read English, and willing to complete four weeks of tracking at Mayo Clinic in Florida. Outcomes will inform whether digital symptom tracking can enhance early symptom awareness and patient engagement in this population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Ages 18-44 years
* Concerned about their GI health
* Able to speak and read English
* Willing to complete a four-week symptom tracking protocol

Exclusion Criteria:

* Unable to understand the informed consent or comply with protocol requirements

Where it's running

• Mayo Clinic in Florida
  Jacksonville, Florida, United States Recruiting

Study contacts

• Principal investigator: Janice Krieger, PhD — Mayo Clinic
• Study coordinator: Enhancing Technology & Communication in Healthcare (ETCH) Lab
• Email: ETCH@mayo.edu
• Phone: 904-953-5375

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Exercise after pelvic radiation to see if it lowers colorectal cancer risk

  This study tests whether regular walking therapy after pelvic radiation for prostate cancer can influence markers of colorectal cancer in colon tissue and blood.

  Recruiting at 2 sites City of Hope Medical Center · Duarte, California and 1 other locations · NCT07790718

• Irreversible Electroporation for Recurrent Pelvic Tumors

  This study tests whether using irreversible electroporation (IRE) is safe and helps control recurrent pelvic tumors in adults who can’t have other local treatments.

  Recruiting Amsterdam UMC, location VUmc · Amsterdam, North Holland · NCT07782164

• Culturally adapted online genetic counseling and testing education for African American cancer survivors

  We will test a culturally adapted online genetic counseling program to see if it increases genetic counseling and genetic testing among African American breast, prostate, and colorectal cancer survivors.

  Recruiting Barbara Ann Karmanos Cancer Institute · Detroit, Michigan · NCT07436078

• Zanidatamab given before surgery for HER2-positive colon or rectal cancer

  This tests whether giving zanidatamab before surgery helps adults with HER2-positive, RAS‑wildtype colon or rectal cancer who are planned for curative treatment.

  Recruiting at 4 sites Phase 2 Emory University · Atlanta, Georgia and 3 other locations · NCT07405476

• In-home cancer treatment with remote specialist support for patients in the Florida Panhandle

  This program will try giving standard cancer treatments at home to people living in the Florida Panhandle and nearby areas to see if they prefer it and have better treatment satisfaction.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT07285044

• Zanidatamab for solid tumors with HER2 changes

  This study will try zanidatamab, an anti-HER2 drug, in adults with advanced endometrial, colorectal, head and neck, sarcoma, or non-small cell lung cancer whose tumors have specific HER2 changes.

  Recruiting at 2 sites Phase 2 Unicancer · Angers and 3 other locations · NCT07192068

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.